Connor McElligott, MD
Interventional Pain Medicine · Sewell, NJNPI 1861998379
Payments from drug & device makers
What this record shows
This record is dominated by grants: $3,333 of the $4,081 with a category attached, or 81.7%. Medtronic accounts for 89.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $3,371 and has fallen 95.7% since, to $145 in 2025.
Across 10 payments — averaging $408.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$185
- Relievant Medsystems, Inc.$111
- Vertos Medical, Inc.$103
- SPR Therapeutics, Inc$29
- KCI USA, Inc.$23
What the payments were for
- Grants$3,33382%
- Food & beverage$74818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 5 | $3,631 |
| Boston Scientific | 1 | $185 |
| Relievant Medsystems, Inc. | 1 | $111 |
| Vertos Medical, Inc. | 1 | $103 |
| SPR Therapeutics, Inc | 1 | $29 |
| KCI USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$3,333
- Intracept$444
- WaveWriter Alpha Prime 16$185
- INCEPTIV$145
- INTELLIS ADAPTIVESTIM$114
- mild Device Kit$103
How this compares
$4,081 in reported general payments places this provider in the 55th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 176 | $1,706 |
| Tizanidine Hcl | 100 | $720 |
| Cyclobenzaprine Hcl | 56 | $457 |
| Pregabalin | 13 | $211 |
| Methylprednisolone | 29 | $167 |
| Tramadol Hcl | 19 | $44 |
| Diazepam | 25 | $28 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Sewell
- Malini KhannaSewell$6K
- Kayla SteeleSewell$3K
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.